Depression and Antidepressants During Pregnancy: Craniofacial Defects Due to Stem/Progenitor Cell Deregulation Mediated by Serotonin

Abstract

Depression is a common and debilitating mood disorder that increases in prevalence during pregnancy. Worldwide, 7 to 12% of pregnant women experience depression, in which the associated risk factors include socio-demographic, psychological, and socioeconomic variables. Maternal depression could have psychological, anatomical, and physiological consequences in the newborn. Depression has been related to a downregulation in serotonin levels in the brain. Accordingly, the most commonly prescribed pharmacotherapy is based on selective serotonin reuptake inhibitors (SSRIs), which increase local serotonin concentration. Even though the use of SSRIs has few adverse effects compared with other antidepressants, altering serotonin levels has been associated with the advent of anatomical and physiological changes in utero, leading to defects in craniofacial development, including craniosynostosis, cleft palate, and dental defects. Migration and proliferation of neural crest cells, which contribute to the formation of bone, cartilage, palate, teeth, and salivary glands in the craniofacial region, are regulated by serotonin. Specifically, craniofacial progenitor cells are affected by serotonin levels, producing a misbalance between their proliferation and differentiation. Thus, it is possible to hypothesize that craniofacial development will be affected by the changes in serotonin levels, happening during maternal depression or after the use of SSRIs, which cross the placental barrier, increasing the risk of craniofacial defects. In this review, we provide a synthesis of the current research on depression and the use of SSRI during pregnancy, and how this could be related to craniofacial defects using an interdisciplinary perspective integrating psychological, clinical, and developmental biology perspectives. We discuss the mechanisms by which serotonin could influence craniofacial development and stem/progenitor cells, proposing some transcription factors as mediators of serotonin signaling, and craniofacial stem/progenitor cell biology. We finally highlight the importance of non-pharmacological therapies for depression on fertile and pregnant women, and provide an individual analysis of the risk–benefit balance for the use of antidepressants during pregnancy

One-drop chemosensing of dapoxetine hydrochloride using opto-analysis by multi-channel μPAD decorated silver nanoparticles: introducing a paper-based microfluidic portable device/sensor toward naked-eye pharmaceutical analysis by lab-on-paper technology

“…2,3 Serotonin, noradrenaline, and dopamine levels in synaptic cles are thought to be out of balance when depressive symptoms start to appear. 4,5 The rst medication initially approved for the on-demand treatment of men with PE (Premature Ejaculation) is dapoxetine hydrochloride (DPX), which belongs to the class of medicines that are called selective serotonin reuptake inhibitors. 6 The DPX causes a delay in ejaculation by blocking the serotonin (5-HT) transporter, which also increases serotonin's activity at the postsynaptic cle.…”

In utero exposure to selective serotonin re‐uptake inhibitor affects murine mandibular development

“…Lifetime risk of major depression among women approaches 25% and is highest during their childbearing years, resulting in an estimated 8% of pregnant women continuing antidepressant therapy throughout pregnancy. Concerns for the health outcomes of newborns in these pregnancies are mounting 1,2 . The once heavily prescribed SSRI, paroxetine (Paxil) has been re‐classified for pregnancy risk from class C to class D, indicating its potential risks to the developing foetus, specifically for cardiac anomalies 3 .…”

“…1,2 The once heavily prescribed SSRI, paroxetine (Paxil) has been re-classified for pregnancy risk from class C to class D, indicating its potential risks to the developing foetus, specifically for cardiac anomalies. 3 Though data correlating use of anti-depressant medications including the commonly prescribed class of selective serotonin re-uptake inhibitors (SSRI) to birth defects remain somewhat controversial, 2,4,5 there are now clinical and pre-clinical reports linking SSRI use and the developmental disruption of the craniofacial skeleton. 1,2 In mammals, multiple bones create the craniofacial skeleton.…”

“…3 Though data correlating use of anti-depressant medications including the commonly prescribed class of selective serotonin re-uptake inhibitors (SSRI) to birth defects remain somewhat controversial, 2,4,5 there are now clinical and pre-clinical reports linking SSRI use and the developmental disruption of the craniofacial skeleton. 1,2 In mammals, multiple bones create the craniofacial skeleton.…”

Anatomical, behavioural and physiological analyses of craniofacial development by cineradiographic imaging in marmosets

“…In addition, the structure of the head is one of the most complex in the entire body. Different tissues with embriologic origins and complex signalling mechanisms seem to be involved during growth and development, 1 and malformations can originate from a variety of causes, including genetic factors, 2 infections, 3 pollutants 4 and prescription drugs 5 . Craniofacial malformations are not uncommon, 6 and their occurrence can cast severe burden on the quality of life of individuals, even after treatment 7 .…”